April, 2016: Senex is mentioned in a BioWorld Insight article that appeared on April 25th.

April, 2016: Senex is granted US patent 9321737, covering its composition of matter.

September 2015: Senex wins Phase I SBIR grant 1R43CA203184 from the National Cancer Institute

January, 2014: Senex establishes a strategic partnership with a foreign company to develop Senex’s lead CDK8 inhibitor as a cancer therapeutic agent in the foreign partner’s territory.

December, 2013: Senex is granted US patent 8598344, covering the composition-of-matter of its selective CDK8/19 inhibitors.

November, 2013: Senex is granted US patent 8592147, covering its drug discovery methodology.

August, 2013: SCRA Technology Ventures invests in Senex

August 6, 2012: a Proc. Natl. Acad. Sci. Article describes a New Class of Drugs for Cancer and Age-related Diseases

September 2011: Senex wins Phase II SBIR grant from the National Cancer Institute.

May 2011: SC Launch invests in Senex

October 2010:  Senex is awarded Therapeutic Discovery Project Grant by the United States Affordable Care Act of 2010

September 2009: Senex wins ARRA Supplement to Phase II SBIR grant 3R44CA139991-03S1 from the National Cancer Institute

June 2009: Senex wins Phase I SBIR grant R43CA141845 from the National Cancer Institute

September 2008: Senex wins Phase II SBIR grant R44CA139991 from the National Cancer Institute

August 2008: Senex wins Department of Defense Breast Cancer Concept Award W81XWH0810611

January 2008: Senex wins Phase I SBIR grant R43GM081968 from the National Institute of General Medical Sciences

January 2007: Senex wins Award ADDF261113 from Alzheimer’s Drug Discovery Foundation

July 2006: Senex wins Phase I SBIR grant R43AG029023 from the National Institute of Aging